glp-1 news november 2025 today Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Pipeline Update: August 2025

Specifically, with a dosage of 140 mg every four weeks, the average percentage change in body weight was a decrease of 2.0% on day 7, and by day 78, after three doses, there was an average weight reduction of 7.4%

Understanding your predispositions does not predict exact medication response, but it can highlight factors your provider should consider during consultation

Intense painMild discomfort is expected after the injection

10.1016/j.tiv.2005.04.001 4 BousmanC

[15] [27] In October 2025, the FDA further expanded the indication for semaglutide (as Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events

If hypoglycaemia is suspected, work with your diabetes team to optimise your medication regimen and meal timing